BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Core Insights - BridgeBio Pharma reported strong commercial progress with 3,751 unique patient prescriptions for Attruby as of August 1, 2025, indicating robust month-over-month growth in treatment-naïve patients [1][3] - The company achieved total second-quarter revenue of $110.6 million, driven by $71.5 million in U.S. Attruby net product revenue, $1.6 million in royalty revenue, and $37.5 million in license and services revenue [1][12] - Attruby's clinical profile was reinforced by new analyses from the ATTRibute-CM study, showing significant benefits for patients, including a 59% relative risk reduction in mortality and a 43% reduction in annual frequency of cardiovascular hospitalization due to atrial fibrillation [1][8] Commercial Progress - The launch of Attruby has accelerated, with nearly double the product revenue this quarter, attributed to growing adoption among healthcare providers [4] - The company ended the quarter with $756.9 million in cash and marketable securities, positioning it well for ongoing commercial activities and upcoming clinical trials [2][9] Pipeline Overview - Key upcoming milestones include topline results from the CALIBRATE study for encaleret in ADH1 expected in fall 2025, and from the PROPEL 3 study for infigratinib in achondroplasia expected in early 2026 [2][11] - The FORTIFY Phase 3 study of BBP-418 for LGMD2I/R9 has completed enrollment, with topline results anticipated in fall 2025 [1][6] Financial Performance - Total revenues for the three months ended June 30, 2025, were $110.6 million, a significant increase from $2.2 million in the same period last year, primarily due to the success of Attruby [12][13] - Operating costs for the quarter were $244.8 million, up from $177.7 million year-over-year, largely driven by increased selling, general, and administrative expenses related to the commercial launch of Attruby [14][15] Key Program Updates - Attruby is positioned as a near-complete transthyretin stabilizer for treating transthyretin amyloid cardiomyopathy (ATTR-CM), with ongoing studies to further validate its efficacy [7][31] - The company is also advancing its pipeline with BBP-418 and encaleret, aiming to address significant unmet needs in genetic diseases [9][11]